A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease
| Autor: | Eira Rawlings, Amy E. Guppy, Peter Amlot, Linda Barber, J. Alejandro Madrigal |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Herpesvirus 4
Human medicine.medical_treatment Biology CD8-Positive T-Lymphocytes medicine.disease_cause Virus Interferon-gamma Immunity Interferon hemic and lymphatic diseases medicine Cytotoxic T cell Humans Interferon gamma Transplantation Immunosuppression Acquired immune system Epstein–Barr virus Kidney Transplantation Lymphoproliferative Disorders surgical procedures operative Treatment Outcome Immunology Cytokines Immunosorbents medicine.drug |
| Zdroj: | Transplantation. 84(11) |
| ISSN: | 0041-1337 |
| Popis: | Reduction of immunosuppression (RIS) to allow development or recovery of Epstein-Barr virus (EBV) immunity can be used to treat EBV-associated posttransplant lymphoproliferative disease (PTLD). Quantification of EBV-specific immunity would help assessment of the efficacy of RIS therapy. Use of intracellular cytokine staining and analysis by flow cytometry to monitor functional EBV-specific T-cell immunity was evaluated in healthy volunteers. The technique was then used to monitor EBV immunity in nine renal transplant patients with PTLD during RIS. The number of interferon (IFN)-gamma producing CD8+ T cells specific for EBV increased distinctly before regression of EBV+ PTLD tumors occurred. The findings confirm the importance of IFN-gamma producing CD8+ T cells in controlling the malignant EBV-transformed B cells of PTLD. The assay effectively quantified EBV immunity during RIS in transplant patients with PTLD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|